Jado Technologies of Dresden has appointed Charl van Zyl as its new chief executive officer, effective 4 September 2007. Mr van Zyl is taking over from Gary Jennings, co-founder of the company, who has been holding the positions of both CEO and chief scientific officer.
Dr Jennings will continue as chief scientific officer.
Mr van Zyl has 11 years of experience in the pharmaceutical industry including holding senior sales and marketing positions at Novartis and Eli Lilly.
Jado is developing cell membrane-targeted drugs using a proprietary platform known as RAFT Intervention Technology.
Source:
Jado Technologies press release 4 September 2007
Copyright 2007 Evernow Publishing Ltd